

Leading Clients Across The Globe



November 2024

Global Life Sciences Capabilities

By the Numbers

1,000+

Life sciences and healthcare industry clients and investors

Top 10

of the largest global pharma/biotech companies

Top 10

of the largest global MedTech/medical device companies

400+

Life sciences and healthcare deals in the last three years

300+

Life sciences and healthcare lawyers globally

50+

years of experience in the industry

For general enquires please contact:
RopesGrayatJefferies2024@ropesgray.com



About Us

Ropes & Gray is the trusted choice for life sciences and healthcare companies, offering innovative solutions to transactional, regulatory, and compliance challenges. Our global team of attorneys, experienced in transactions, life sciences and health care regulatory, data privacy, IP, and government enforcement, helps clients make sense of the complex landscape and develops creative solutions in domestic and cross-border matters.

With over 300 life sciences and health care attorneys, we offer extensive expertise across the entire biopharma ecosystem, making us a trusted partner in navigating the industry's complexities worldwide.

Drawing upon our historical strengths in the life sciences industry, our multidisciplinary team partners and collaborates seamlessly across practices, offices, and jurisdictions. Ropes & Gray develops creative and practical solutions for life sciences companies, ensuring comprehensive and integrated support throughout their journey.

Specializations


- Venture, growth and crossover investments
- Licensing and collaborations
- Mergers, acquisitions and divestitures
- Private equity transactions
- Regulatory and compliance counseling
- Patent strategy and diligence
- Antitrust and competition
- Drug pricing strategy
- Transactional tax

“On any issue that arises, they have an expert who can help with clear, concise advice.”





— Client, *Chambers Global*

Highlights of Our Global Experience





Venture Investment

 <p>Advised Novalis Lifesciences in its Series B investment in Ori Biotech, a leader in cell and gene therapy manufacturing technology</p>	 <p>Advised Northpond in its Series A investment in Ansa, a developer of a novel DNA synthesis technology</p>	 <p>Advised Northpond in its Seed investment in Mestag, a breakthrough inflammatory disease and immuno-oncology company</p>	 <p>Advised Sands Capital Management in its Series D financing in Freenome, a comprehensive biotechnology company</p>
--	--	--	--





Corporate Venture Investment

 <p>Advised Pfizer Ventures in its \$25 million minority investment in CellCentric, a UK-based clinical stage biotechnology company</p>	 <p>Advised Pfizer Ventures in its \$35 million minority investment in Dublin-based Carrick Therapeutics</p>	 <p>Advised Sanofi in a strategic equity investment in Italy-based Resalis, a biotech addressing metabolic disorders such as obesity and fatty liver disease</p>	 <p>Advised JJDC on its equity investment in France-based Nanobiotix, a late-clinical stage biotechnology company</p>
---	---	---	--





Emerging Company

 <p>Advised UK-based Basecamp Research in its \$60 million Series B funding round</p>	 <p>Advised AvenCell Therapeutics in its \$112 million Series B funding round</p>	 <p>Advised Areteia Therapeutics in its \$350 million Series A financing</p>	 <p>Advised Population Health Partners on the formation of Metsera and \$290 million financing</p>
---	--	---	---




Licensing and Collaborations

 <p>Advised Novo Nordisk in its collaboration agreement with Flagship and Metaphor to develop up to two next-generation obesity therapeutics</p>	 <p>Advised Italy-based Chiesi in its global strategic collaboration with Gossamer to develop and commercialize Gossamer's seralutinib</p>	 <p>Advised MOMA in a collaboration and exclusive license agreement with Bayer to develop and commercialize MOMA's KNOMATIC platform</p>	 <p>Advised Monte Rosa in a strategic collaboration with Roche for Monte Rosa to leverage its QuEEN platform for molecular glue degraders</p>
---	---	---	--





Mergers & Acquisitions

 <p>Advised TESARO in its \$5.1 billion sale to GSK, a UK-based pharmaceutical company</p>	 <p>Advised Shire, a UK-based pharmaceutical company, in its \$32 billion acquisition of Baxalta</p>	 <p>Advised Provention Bio in its \$2.9 billion sale to Sanofi, a French-based pharmaceutical company</p>	 <p>Advised G1 Therapeutics in its merger with Pharmacosmos, a Denmark-based biotech company</p>
--	---	--	---

Antitrust and Competition

 <p>Advised Alexion's FTC defense of its acquisitions of Achillion for \$930 million upfront and Syntimmune for up to \$1.2 billion</p>	 <p>Advised AbbVie in its \$21 billion acquisition of Pharcyclics, which obtained FTC approval without Second Request</p>	 <p>Advised Cubist before the FTC in its \$9 billion combination with Merck without Second Request</p>	 <p>Advised Acceleron Pharma before U.S. and foreign authorities in its \$11.5 billion sale to Merck</p>
---	--	---	---

Private Equity Transactions

 <p>Advised Partners Group in its acquisition of Pharmathen, a Greece-based pharmaceutical company and, subsequently, Pharmathen on its acquisition of CBL Patras</p>	 <p>Advised GHO Capital and its portfolio company Envision Pharma Group in its acquisition of OKRA.ai, a UK-based technology company</p>	 <p>Advised Avista Capital Partners and Nordic Capital in its sale of Acino, a Switzerland-based pharmaceutical company</p>	 <p>Advised TPG Capital and its portfolio company BVI Medical in its acquisition of Malosa Medical, a UK-based medical device company</p>
---	---	--	--

Award-Winning, Reliable Service

Corporate Firm of the Year & United Kingdom Firm of the Year

LMG Life Sciences Awards EMEA 2024

Licensing and Collaboration Firm of the Year

Two-time winner
LMG Life Sciences Awards

Firm of the Year IP Transactions

Managing IP Americas 2023

M&A Firm of the Year

LMG Life Sciences 2022

Top-Tier Life Sciences Regulatory/ Compliance Practice

Chambers USA 2024

UK Life Sciences Firm of the Year

LMG Life Sciences EMEA Awards 2024

Leading Firm

Leading Firm Multi-Jurisdictional: Life Sciences
Chambers Global 2024

Corporate Practice of the Year

Pharma and Health Care
The American Lawyer Industry Awards 2022 & 2024

14 offices worldwide

